| Literature DB >> 28453572 |
Divay Chandra1, Aman Gupta1, Joseph K Leader2, Meghan Fitzpatrick1, Lawrence A Kingsley3, Eric Kleerup4, Sabina A Haberlen5, Matthew J Budoff4, Mallory Witt4, Wendy S Post5,6, Frank C Sciurba1, Alison Morris1.
Abstract
RATIONALE: Individuals with HIV are at increased risk for coronary artery disease (CAD). Early detection of subclinical CAD by assessment of coronary artery calcium (CAC) may help risk stratify and prevent CAD events in these individuals. However, the current standard to quantify CAC i.e. Agatston scoring requires EKG-gated cardiac CT imaging.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28453572 PMCID: PMC5409142 DOI: 10.1371/journal.pone.0176557
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characteristics of study participants stratified by presence/absence of coronary artery calcium defined by Weston or Agatston scores (median (IQR) for continuous variables and proportion for categorical variables).
| Variable | All | Weston score | Agatston score | ||||
|---|---|---|---|---|---|---|---|
| No CAC | Yes CAC | No CAC | Yes CAC | ||||
| 108 | 47 | 61 | 44 | 64 | |||
| Age, years | 55.2 (50.4; 59.9) | 53.4 (48.3; 58.7) | 57.6 (52.2; 61.3) | 52.1 (47.8; 56.5) | 57.7 (53.4; 62.1) | ||
| Race (%) | 0.08 | ||||||
| Non-Hispanic White | 86 (79.6) | 33 (75.0) | 53 (88.3) | 29 (70.7) | 57 (90.5) | ||
| Other | 18 (16.7) | 11 (25.0) | 7 (11.7) | 12 (29.3) | 6 (9.5) | ||
| Seropositive (%) | 62 (57.4) | 28 (59.6) | 34 (55.7) | 0.69 | 26 (59.1) | 36 (56.2) | 0.77 |
| CD4 count ( | 711.5 (560.0; 955.0) | 721.0 (587.0; 892.0) | 693.0 (558.0; 980.0) | 0.68 | 726.0 (587.0; 892.0) | 693.0 (556.0; 984.0) | 0.80 |
| Viral load ( | 49.0 (19.0; 49.0) | 44.0 (19.0; 49.0) | 49.0 (19.0; 49.0) | 0.75 | 41.5 (19.0; 49.0) | 49.0 (19.0; 49.0) | 0.63 |
| ART ( | 58 (53.7) | 25 (53.2) | 33 (54.1) | 0.92 | 23 (52.3) | 35 (54.7) | 0.80 |
| Current smoking (%) | 29 (26.9) | 11 (23.4) | 18 (29.5) | 0.44 | 11 (25.0) | 18 (28.1) | 0.76 |
| Pack years of smoking | 2.8 (0.0; 22.0) | 0.8 (0.0; 17.3) | 5.3 (0.0; 29.0) | 0.14 | 0.7 (0.0; 17.2) | 4.5 (0.0; 29.5) | 0.17 |
| BMI (kg/m2) | 26.5 (23.8; 30.5) | 25.8 (23.4; 29.4) | 26.8 (24.2; 32.1) | 0.06 | 25.8 (23.5; 28.0) | 26.8 (24.2; 32.1) | 0.05 |
| Hypertension (%) | 54 (50.0) | 22 (48.9) | 32 (58.2) | 0.35 | 19 (45.2) | 35 (60.3) | 0.14 |
| Diabetes mellitus (%) | 10 (9.2) | 5 (11.1) | 5 (9.3) | 0.76 | 5 (11.6) | 5 (8.9) | 0.65 |
| Hyperlipidemia (%) | 87 (80.5) | 37 (78.7) | 50 (84.7) | 0.45 | 34 (77.3) | 53 (85.5) | 0.26 |
| Total cholesterol (mg/dL) | 184.0 (159.0; 204.0) | 186.0 (159.0; 204.0) | 182.0 (159.0; 207.0) | 0.53 | 185.5 (158.0; 205.0) | 182.5 (160.0; 203.0) | 0.70 |
| HDL cholesterol (mg/dL) | 46.0 (37.5; 54.5) | 50.3 (38.0; 65.9) | 42.9 (37.0; 50.2) | 51.5 (40.4; 65.9) | 42.7 (36.9; 50.4) | ||
| LDL cholesterol (mg/dL) | 107.0 (86.0; 124.5) | 112.0 (86.0; 130.0) | 105.0 (84.0; 122.0) | 0.49 | 109.5 (84.5; 130.5) | 106.5 (86.0; 122.0) | 0.90 |
| Triglycerides (mg/dL) | 124.0 (82.0; 194.0) | 109.5 (74.0; 162.0) | 130.0 (87.0; 216.0) | 0.07 | 105.0 (74.0; 152.5) | 134.0 (88.0; 217.0) | |
| Hemoglobin A1c (%) | 5.5 (5.3; 5.8) | 5.5 (5.3; 5.8) | 5.6 (5.3; 5.8) | 0.60 | 5.5 (5.3; 5.8) | 5.6 (5.3; 5.8) | 0.51 |
| Fasting glucose (mg/dL) | 97.0 (90.0; 104.0) | 96.0 (90.0; 101.0) | 98.0 (91.0; 109.0) | 0.22 | 95.0 (89.0; 100.0) | 98.0 (92.0; 108.0) | 0.05 |
| C-reactive protein (mg/dL) | 1.0 (0.6; 2.5) | 0.9 (0.5; 2.2) | 1.2 (0.6; 2.7) | 0.44 | 1.1 (0.6; 2.3) | 1.0 (0.5; 2.6) | 0.78 |
| Framingham 10-yr risk | 0.16 | 0.10 | |||||
| Low (<10%) | 69 (65.1) | 33 (70.2) | 36 (61.0) | 33 (75.0) | 36 (58.1) | ||
| Intermediate (10–20%) | 29 (27.4) | 13 (27.7) | 16 (27.1) | 10 (22.7) | 19 (30.6) | ||
| High (>20%) | 8 (7.5) | 1 (2.1) | 7 (11.9) | 1 (2.3) | 7 (11.3) | ||
* p values are from Wilcoxon rank-sum test for continuous variables, and from chi-square test for categorical variables
† ART = combination antiretroviral therapy
‡ Measured blood pressure ≥140 systolic or ≥90 diastolic, or use of antihypertensive medication with prior diagnosis of hypertension
§ Hemoglobin A1C≥6.5 or fasting blood glucose ≥126 mg/dL or participant report of use of medication for diabetes with prior diagnosis of diabetes
** Fasting total cholesterol ≥ 200 mg/dl or LDL cholesterol ≥130 mg/dl or HDL < 40 mg/dl or triglycerides > = 150 mg/dl, or participant report of the use of medication to treat dyslipidemia with prior diagnosis of hyperlipidemia
Fig 1ROC curves for the selection of the optimal cut point for the Weston score that corresponds to the established cut point of 100 (panel A) and 400 (panel B) for the Agatston score.
Inter observer agreement for Weston coronary artery calcium score, n = 21 scans.
| κw | |
|---|---|
| 0.90 | |
| Left main | 0.79 |
| Left anterior descending | 0.92 |
| Right coronary | 0.86 |
| Left circumflex | 0.82 |
Fig 2Correlation between Weston and Agatston scores performed on 108 individuals.
Comparison of category of coronary artery calcium defined by Weston compared with Agatston scores.
The categories for Agatston score are: none = 0, mild = 1–100, moderate = 101–400, and severe>400. Categories for Weston score are: none = 0, mild = 1–2, moderate = 3–7, and severe = 8–12.
| Weston score | Agatston score in all comers κw = 0.77, | Total | Agatston score among HIV seropositive men κw = 0.82, | Total | Agatston score among HIV seronegative men κw = 0.68, | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| None | Mild | Moderate | Severe | None | Mild | Moderate | Severe | None | Mild | Moderate | Severe | ||||
| None | 5 | 0 | 0 | 47 | 3 | 0 | 0 | 28 | 2 | 0 | 0 | 19 | |||
| Mild | 2 | 2 | 0 | 17 | 1 | 1 | 0 | 10 | 1 | 1 | 0 | 7 | |||
| Moderate | 0 | 11 | 1 | 29 | 0 | 5 | 0 | 14 | 0 | 6 | 1 | 15 | |||
| Severe | 0 | 0 | 8 | 15 | 0 | 0 | 3 | 10 | 0 | 0 | 5 | 5 | |||
| 44 | 29 | 27 | 8 | 26 | 16 | 13 | 7 | 18 | 13 | 14 | 1 | ||||